Preparation
Angimet® MR Tablet: Each Modified Release tablet contains Trimetazidine Dihydrochloride BP 35 mg.
Angimet® Tablet: Each Film-coated tablet contains Trimetazidine Dihydrochloride BP 20 mg.
Indication
Treatment option for angina pectoris & Heart failure.
Contraindication
Hypersensitivity: This medicine is not recommended for use in patients with hypersensitivity to Trimetazidine.
Parkinson's disease: This medicine is not recommended for use in patients with Parkinson's disease since it may worsen the symptoms of Parkinson's.
Severe renal impairment: Trimetazidine is not recommended for use in patients with severe renal impairment due to the increased risk of worsening of the patient's condition.
Dosage & Administration
Angimet® MR Tablet: One tablet two times daily.
Angimet® Tablet: One tablet three times daily.
Side Effect
Trimetazidine is safe and well tolerated. The most commonly encountered side effects are gastric discomfort, nausea, headache and vertigo. However, the side effects are mild and non-specific.
Precaution
Drowsiness: This medicine may cause drowsiness. It is advised that you do not perform any activities that require high mental alertness such as driving a vehicle during treatment with this medicine.
Hypotension: Trimetazidine may cause hypotension. This risk is especially higher in patients undergoing treatment with high blood pressure medicines. Close monitoring of blood pressure and appropriate dose adjustments may be required based on the clinical condition.
Drug Interaction
No drug interactions so far have been reported. In particular, no interactions have been reported with beta-blockers, calcium antagonists, nitrates, heparin, hypolipidemic agents or digitalis preparations.
Presentation
Angimet® MR Tablet: Each box contains 3 x 10 tablets in Alu-Alu blister pack.
Angimet® Tablet: Each box contains 5 x 10 tablets in Alu-Alu blister pack.
Contraindications
Hypersensitivity to Trimetazidine Dihydrochloride.
Use Children
Safety and efficacy in children have not been established with Trimetazidine.
Use Pregnancy Lactation
Pregnancy: Studies in animals have not demonstrated a teratogenic effect. However, in the absence of clinical data and for safety reasons, prescription should be avoided during pregnancy.
Lactation: In the absence of data, breastfeeding is not recommended during treatment.
Overdosage
Seek emergency medical treatment or contact the doctor in case of an overdose.
Storage
Store at temperature below 30 °C in a cool and dry place, away from light. Keep all medicines out of the reach of children.
